Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Connect with us

Hi, what are you looking for?

slide 3 of 2
THE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & LifestyleTHE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & Lifestyle

Business

Business

Bristol-Myer’s New Melanoma Drug Receives Accelerated Approval

Bristol Myers Squibb Bristol Myers Squibb
Bristol Myers Squibb Bristol Myers Squibb

Bristol-Myers Squibb is one the leading pharmaceutical companies around the world, and they were just granted approval from the Food and Drug Administration to start releasing a new drug that will help patients with Melanoma.

Opdivo is the new drug being released by BMS, after being confirmed as a beneficial drug that will severely help patients who are diagnosed with Melanoma.

There is an estimated 76,100 people in the United States alone that suffer from this deadly skin disease, and a good majority of those infected with the disease may die at the hands of it. According to the FDA’s official website, Melanoma is the fifth most common type of cancer in the United States, and forms within the melanocyte cells, the cells that are responsible for developing skin pigmentation. Researchers have been trying to find new ways to cure this common disease, and there have been seven drugs approved the FDA for Melanoma since 2011.

The drug reportedly works by shrinking tumors on the skin for patients, and it goes after cancer cells. The drug was not going to be released just yet, but received accelerated approval after one third of the patients who were in trial with it showed signs of tumor shrinkage.

While Melanoma is a deadly disease, the approval of Opdivo has given a lot of people a chance at fighting this condition.

 

 


Comment Template

You May Also Like

Business

**Excerpt:** Bong Joon-ho’s visionary approach to filmmaking shines once again as stars Toni Collette and Naomi Ackie reveal insights into his creative process for...

Business

**Excerpt:** Bong Joon-ho’s *Mickey 17* is a sci-fi masterpiece that cements his status as one of the most visionary filmmakers of our time. Starring...

Business

**Excerpt:** Bong Joon-ho, the visionary director behind *Parasite*, returns with *Mickey 17*, a sci-fi thriller based on Edward Ashton’s novel *Mickey7*. Starring Robert Pattinson,...

Business

**Excerpt from *I, Rodion* by Alexandra Pugachevsky** The air on the colony ship *Elysium* was stale, recycled too many times to count. Rodion adjusted...

Notice: The Biznob uses cookies to provide necessary website functionality, improve your experience and analyze our traffic. By using our website, you agree to our Privacy Policy and our Cookie Policy.

Ok